



**HAL**  
open science

# Intestinal Availability and Metabolic Effects of Dietary Camelina Sphingolipids during the Metabolic Syndrome Onset in Mice

Dominique Hermier, Annaig Lan, Frédérique Tellier, Anne Blais, Marta Culetto, Véronique Mathe, Yannick Bellec, Lionel Gissot, Philippe Schmidely, Jean-Denis Faure

## ► To cite this version:

Dominique Hermier, Annaig Lan, Frédérique Tellier, Anne Blais, Marta Culetto, et al.. Intestinal Availability and Metabolic Effects of Dietary Camelina Sphingolipids during the Metabolic Syndrome Onset in Mice. *Journal of Agricultural and Food Chemistry*, 2020, 68 (3), pp.788-798. 10.1021/acs.jafc.9b06829 . hal-02463037

**HAL Id: hal-02463037**

**<https://agroparistech.hal.science/hal-02463037>**

Submitted on 21 Oct 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **bioavailability** and metabolic effects of dietary camelina sphingolipids during the metabolic  
2 syndrome onset in mice.

3 Dominique Hermier<sup>1</sup> \*, Annaïg Lan<sup>1</sup>, Frédérique Tellier<sup>2</sup>, Anne Blais<sup>1</sup>, Marta Grauso Culetto<sup>1</sup>  
4 Véronique Mathé<sup>1</sup>, Yannick Bellec<sup>2</sup>, Lionel Gissot<sup>2</sup>, Philippe Schmidely<sup>3</sup>, Jean-Denis Faure<sup>2</sup>.

5 <sup>1</sup>, UMR Physiologie de la Nutrition et du Comportement Alimentaire, AgroParisTech, INRA,  
6 Université Paris-Saclay, 75005, Paris, France

7 <sup>2</sup>, Institut Jean-Pierre Bourgin, INRA, AgroParisTech, CNRS, Université Paris-Saclay, 78000,  
8 Versailles, France

9 <sup>3</sup>, UMR Modélisation systémique Appliquée aux Ruminants, AgroParisTech, INRA, Université  
10 Paris-Saclay, 75005, Paris, France

11

12 \*, corresponding author:

13 Dominique Hermier, UMR Physiologie de la Nutrition et du Comportement Alimentaire,  
14 AgroParisTech, 16 rue Claude Bernard, F-75005 Paris, France

15 Phone : 33(1)44087246

16 Fax: (33)144081858

17 Email: dominique.hermier@agroparistech.fr

18

19

20 **ABSTRACT.**

21 Sphingolipids appear as a promising class of components susceptible to prevent the onset of  
22 the metabolic syndrome (MetS). Gut availability and effects of *Camelina sativa* sphingolipids  
23 were investigated in a mouse model of dietary-induced metabolic syndrome. Seed meals  
24 from two *Camelina sativa* lines enriched respectively in C24- and C16- NH<sub>2</sub>-glycosyl-inositol-  
25 phosphoryl-ceramides (NH<sub>2</sub>GIPC) were used in hypercaloric diets. After 5 weeks on these  
26 two hypercaloric diets, two markers of the MetS were alleviated (adiposity and insulin  
27 resistance) as well as inflammation markers and colon barrier dysfunction. A more  
28 pronounced effect was observed with the C16-NH<sub>2</sub>GIPC-enriched HC diet, in particular for  
29 colon barrier function. Despite a lower digestibility, C16-NH<sub>2</sub>GIPC were more prevalent in  
30 the intestine wall. Sphingolipids provided as camelina meal can therefore counteract some  
31 deleterious effects of a hypercaloric diet in mice at the intestinal and systemic levels.  
32 Interestingly, these beneficial effects seem partly dependent on sphingolipid acyl chain  
33 length.

34

35

36

37 **Key words:** sphingolipid, *Camelina sativa*, metabolic syndrome, digestibility, acyl chain.

## 38 INTRODUCTION

39 The metabolic syndrome (MetS) is a cluster of abnormalities including visceral obesity,  
40 dyslipidemia, hyperglycemia, and increased blood pressure, which results in a higher risk of  
41 cardiovascular diseases and type-2 diabetes <sup>(1)</sup>.

42 Its prevalence is increasing worldwide and makes it a major public health challenge. This  
43 increase is associated with several features of lifestyle such as physical inactivity,  
44 psychosocial stress, environmental contaminants, and, as a major determinant, dietary  
45 habits <sup>(2)</sup>. High caloric intake, typical of Western-type diet rich in saturated fatty acids (SFA)  
46 and sugars, is a major causative factor of the onset of the MetS, which is characterized by  
47 early events such insulin resistance (IR) and a low-grade inflammation (LGI) <sup>(3, 4)</sup>. These  
48 alterations are known to originate, at least partly, from an allostatic stress due to the  
49 Western-type diet, which is characterized by microbial dysbiosis <sup>(5)</sup>, together with local  
50 inflammation <sup>(6)</sup> and physiological dysfunction of the intestinal wall <sup>(3)</sup>. The resulting  
51 endotoxemia enhances the low-grade inflammation (LGI) at the systemic level, which, in  
52 turn, amplifies the initiation of the MetS <sup>(7, 8)</sup> In addition to the rodent studies, both  
53 observation and intervention human studies confirmed the link between nutrients, gut  
54 dysfunction, LGI and initiation of the MetS, and in particular IR <sup>(8, 9)</sup>.

55 In consequence, new preventive and therapeutic strategies for MetS, including lifestyle-  
56 based changes involving nutrition, must be established, tested and improved in specifically  
57 susceptible and vulnerable people, such as the at-risk, obese subjects. In these patients, the  
58 challenge is to prevent or delay the onset of IR and low-grade inflammation, and of cardio-  
59 metabolic complications. Among the different possible solutions are diet changes and/or  
60 diet complementation.

61 As part of dietary candidates susceptible to prevent or alleviate the onset of the MetS, and

62 particularly of IR, sphingolipids (SL) appear as a new and promising class of components.  
63 Indeed, body SL originate from endogenous synthesis, but may also be provided by the diet  
64 from animal or vegetal products. SL are composed of a sphingoid base (or long-chain base,  
65 LCB) acylated by a long or very long-chain FA and bearing a more or less complex polar head  
66 group <sup>(10)</sup>. They are essential components of cell membranes and are involved in cell  
67 signalling in both plants and animals. They are associated, together with animal cholesterol  
68 or plant phytosterols, into membrane micro-domains (caveolae and lipid rafts) <sup>(11)</sup>. These  
69 micro-domains are more ordered and less fluid than the rest of the plasma membrane,  
70 which favours docking, clustering and functionality of insulin receptor and other membrane  
71 receptors <sup>(11, 12)</sup>. Interestingly, the length of the SL acyl chain is an important structural  
72 feature modulating the properties of these micro-domains and subsequent translocation  
73 and downstream signalling of insulin receptor <sup>(13)</sup>. A number of disparate, but convincing  
74 data, suggest that some plant SL (phytoSL) would improve some features of the MetS, such  
75 as dyslipidemia <sup>(14, 15)</sup>, IR/glucose intolerance <sup>(15-18)</sup> and non-alcoholic steatohepatitis <sup>(14, 18-20)</sup>.  
76 There is also some evidence that dietary SL from both animal and plant origin may exert  
77 anti-inflammatory effects at the extra-digestive level, including in the postprandial state <sup>(21,</sup>  
78 <sup>22)</sup>.

79 Other beneficial effects of phytoSL have been described at the intestine level, in mice  
80 models of chemically-induced colorectal cancer or inflammatory bowel diseases <sup>(23-28)</sup>. In  
81 contrast, when it comes to nutritionally-induced rather than chemically-induced, allostatic  
82 intestinal stress, it remains unknown if dietary phytoSL may alleviate microbial dysbiosis  
83 and/of gut barrier function alterations, which could explain some beneficial systemic  
84 consequences.

85 The mechanisms by which phytoSL exert their beneficial effects are still not elucidated and

86 since it is a large and diversified lipid family, the role of the different structural components  
87 (polar head, acyl chains, long chain base) remains to be deciphered. Indeed, plants have a  
88 large variety of SL with more than 300 molecular species, some of which being tissue specific  
89 <sup>(29)</sup>. They are characterized by specific polar heads like glycosyl-inositol-phosphoryl-  
90 ceramides (GIPC) and LCB like phytosphingosine (PHS, t18:1). Seeds also accumulate specific  
91 amino-derivate GIPC (NH<sub>2</sub>GIPC) <sup>(29)</sup>.

92 Taken together, available data suggest that plant-derived SL can have beneficial effects on  
93 the MetS onset. However, all previous studies were performed by using purified SL and,  
94 most often, plant SL were administered orally or intra-peritoneally, and not as diet  
95 ingredient. The objective of the present study was therefore to assess (i) whether plant SL  
96 provided as part of the diet (i.e. as a food ingredient in a food matrix) could counteract MetS  
97 onset and (ii) whether SL acyl chain length is important in modulating the physiological and  
98 metabolic impact of dietary phytoSL. Because bioavailability is an essential prerequisite to  
99 extra-digestive effects, digestibility of phytoSL with different acyl chain length had also to be  
100 determined. Plant SL originating from two isogenic camelina cultivars in which SL were  
101 differing only by their **fatty acid (FA)** chain length were provided as seed meal to mice fed for  
102 5 weeks with high-fat/high sucrose diets. The first outcome was to assess the bioavailability  
103 of dietary phytoSL **at the digestive level**, by using plant sphingolipidomic profiling, and their  
104 possible impact on intestinal function. The second one was to evaluate if dietary phytoSL  
105 could slower the onset of the MetS, especially as regards dyslipidemia and IR. Finally, the  
106 hypothesis that acyl chain length may modulate digestibility and bioactivity of phytoSL was  
107 also tested for both the outcomes.

108

109

110 **MATERIALS AND METHODS**

111 **Selection of C16-SL accumulating camelina line.** *Camelina sativa* cultivar "Céline" was grown  
112 in glasshouse conditions as described previously<sup>(30)</sup>. To generate plants accumulating SL rich  
113 in C16 FA (C16-SL), the coding sequence of the Arabidopsis ceramide synthase AtLOH2  
114 (At3g19260) was PCR amplified using LOH2EcoRI-F and LOH2XhoI-R primers modified with  
115 EcoRI and XhoI restriction enzymes (LOH2EcoRI-F, GGAATTCATGGAATCGGTATCATCACG;  
116 LOH2XhoI-R, CCGCTCGAGCTAATCATCATCATCCTCTG) and cloned behind the soybean glycinin  
117 promoter into the pBinGlyRed2 vectors after removal of the Luciferase coding sequence  
118 using the EcoRI/XhoI enzymes. Plants were transformed by flower dip infiltration with  
119 *Agrobacterium tumefaciens* carrying pBinGlyRed2::AtLOH2 and T1 seeds were selected  
120 based on their red fluorescence<sup>(31)</sup>. A total of 107 T2 progeny were produced and screened  
121 for their respective seed SL content by LC-MS/MS. Eight T3 progeny were eventually  
122 selected and amplified and rescreened for their seed SL content. A homozygous line named  
123 LOH2<sup>Y</sup> with the highest C16-SL content was finally selected and amplified as T4 and T5  
124 generations. Complete SL profile was carried out on T5 seeds, as described below.

125 A total of 1476 wild type camelina and 1593 LOH2<sup>Y</sup> T4 plants were cultivated side by side  
126 in the glasshouse, resulting in the production of 6.1 kg of Céline seeds (of which SL-FA are  
127 mostly C24) and 5.4 kg of T5 LOH2<sup>Y</sup> seeds (rich in C16-SL). Camelina seeds were crushed with  
128 an Oilprinz KK8 F universal (Kern Kraft, Reut, Germany) at 60 rpm and with opening of 8 mm  
129 to produce CamC24 and CamC16 meal and oil from Céline and LOH2<sup>Y</sup> seeds respectively.  
130 Macronutrient composition of the camelina meal was determined as previously described  
131<sup>(32)</sup> and was (in weight %): 36.5/39.4 protein, 19.7/19.8 lipid, 29.4/28.8 fibre, 5.79/5.83 ashes  
132 and 5.70/5.81 humidity for the CamC24 and CamC16, respectively. Fibre typology was the  
133 same in both meals (data not shown).

134

135 **Animals and diets.** Thirty-three 7-week old male C57BL/6J01aHSD mice (Envigo, Gannat,  
136 France) were housed in individual cages with wired floor, at  $22 \pm 1^\circ\text{C}$  under 12-h light/dark  
137 cycles (light on at 07:00 am) and acclimated to local conditions for 1 week. During the last 3  
138 days of the week, 27 mice were progressively switched from the standard pelleted chow diet  
139 (SAFE A04, Augy, France) to the control hypercaloric (HC-Con) diet (see below). At 8 weeks  
140 of age, mice were divided into 4 groups and fed during 5 weeks with either the same chow  
141 diet as before (normocaloric diet, NC group, n=6) or one of the three hypercaloric (HC) diets,  
142 two providing one of the two camelina meals (HC-CamC24 and HC-CamC16, n=9) and the  
143 third one a control HC diet (HC-Con n=9) (**Supplemental Table 1**). Mice had free access to  
144 food and tap water. Individual body weight was recorded weekly. The study was performed  
145 according to the European directive for the use and care of laboratory animals  
146 (2010/63/UE), and received the agreement of the local animal ethics committee and of the  
147 ministerial committee for animal experimentation (Ref 20151I0317422745.v4-APAFIS#2701).

148 HC diets were prepared freshly twice a week, stored at  $4^\circ\text{C}$ , and provided daily to mice as  
149 soft pellets. CamC24 and CamC16 meals from the commercial Céline cultivar and LOH2<sup>Y</sup> line  
150 were incorporated into the HC diets (respectively HC-CamC24 and HC-CamC16). Camelina oil  
151 obtained from Céline seed crushing was kept at  $4^\circ\text{C}$  and incorporated into the HC-Con diet at  
152 the same level as in the two HC-CamC24 and HC-CamC16 diets. It contains as previously  
153 described mostly polyunsaturated FA (53%) and monounsaturated FA (29%), as previously  
154 described <sup>(31)</sup>. **SL analysis of this oil showed the absence of NH<sub>2</sub>GIPC, the major SL in both**  
155 **camelina meals.**

156 Sphingolipid were extracted from camelina meals, **oils** and diets, as described previously  
157 <sup>(29)</sup>. CamC24 and CamC16 meals contained the same levels (in nmol/g) of total phytoSL and



158 NH<sub>2</sub>GIPC, which was the major SL in both meals (92%) (**Supplemental Table 2**). In contrast,  
159 C24-NH<sub>2</sub>GIPC accounted for 82% of total NH<sub>2</sub>GIPC in CamC24, whereas C16-NH<sub>2</sub>GIPC  
160 accounted for 90% of total NH<sub>2</sub>GIPC in CamC16. The amount of camelina meals to be  
161 incorporated into the HC-CamC24 and HC-CamC16 diets (107g/kg) was calculated according  
162 to the SL content of the camelina meals, the mice food intake (about 4 g/d for a HC diet) and  
163 the amount of purified plant SL given to rodents in the literature (4-8 mg/d in mice, without  
164 indication of their body weight)<sup>(14, 16)</sup>. SL profile of the HC-CamC24 and HC-CamC16 diets  
165 reflected that of the respective meals, with NH<sub>2</sub>GIPC being the major SL with mostly by 24  
166 carbons FA in CamC24 meal, and by 16 carbons FA in CamC16 meal (**Table 1**). As expected,  
167 HC-Con diet contained very little NH<sub>2</sub>GIPC, whereas the NC diet was surprisingly rich in SL,  
168 and especially in NH<sub>2</sub>GIPC, probably as a consequence of the high level of plant-based  
169 materials (e.g. soya bean) in the commercial chow.

170

171 ***In vivo* measurements and sample collection.** Food intake during 48 h was monitored after  
172 6 d and 4 wk on the experimental diets. Feces were collected and weighed for further  
173 lipidomics at the end of the 48 h. Part of the feces was freeze-dried before assaying the dry  
174 matter content<sup>(32)</sup>. Apparent digestibility of the dry matter was calculated as follows:  
175 (intake-feces content)/intake\*100. SL apparent digestibility was calculated by applying the  
176 same formula to SL content measured in food and feces.

177 The body composition (fat mass and lean mass) was measured *in vivo* after 3 weeks on  
178 the experimental diets by dual energy X-ray absorptiometry (DEXA), using a Lunar PIXImus  
179 densitometer (GE Medical Systems, Buc, France). The stability of the device was controlled  
180 by a measurement of a phantom before each session. The mice were anesthetized by  
181 isoflurane inhalation during the measurement. Analysis of the images was performed with

182 the software provided with the device (Lunar PIXImus v2.10, GE Medical Systems, Buc,  
183 France), using auto-thresholding.

184 An oral glucose tolerance test (OGTT) was performed after 3 weeks on the experimental  
185 diets. Six hours fasted mice were weighed and a blood sample (~25 µL) was taken from the  
186 tail vein ~15 min before (t0) gavage, then after 15, 30, 60, and 120 min following orally  
187 administration of a glucose solution (2 g/kg). Blood glucose concentration was immediately  
188 assayed using a standard glucometer (Onetouch, LifeScan, Boulogne-Billancourt, France).  
189 Blood was centrifuged (10 min, 1600 g, 4°C) and plasma stored at -20°C for subsequent  
190 assay of insulin.

191 After 5 weeks on the experimental diets, mice were fasted for 6 h. After a blood sample  
192 has been taken from the tail vein for glucose determination, mice were deeply anesthetized  
193 by isoflurane inhalation (IsoFlo, Axience, Pantin, France). Blood was taken by cardiac  
194 puncture before mice were euthanized by exsanguination. The abdominal cavity was then  
195 opened and the following parts were removed and weighed: liver, epididymal adipose  
196 tissue (EpAT), kidneys, spleen, small intestine, caecum and colon. The luminal contents of  
197 the caecum and the colon were removed and weighed. Jejunum, colon and EpAT samples  
198 were snap-frozen in liquid nitrogen and stored at -80°C. Blood samples were centrifuged as  
199 described above for plasma extraction and storage.

200

201 **Ex vivo intestinal measurements.** To assess potential changes in intestinal barrier function,  
202 electrophysiological measurements were performed as previously described <sup>(33)</sup> with the  
203 following modifications: each mouse proximal colon was opened along the mesenteric line  
204 and mounted on an EasyMount Ussing chamber insert (Physiologic Instrument Inc, San  
205 Diego, CA, USA) with an exposed area of 0.2 cm<sup>2</sup>. Mounted tissues were left to equilibrate

206 their trans-epithelial potential ( $V_t$ , mV) 45 min before clamping them to 0 mV to obtain the  
207 short-circuit current ( $I_{sc}$ ,  $\mu\text{A}/\text{cm}^2$ ). The trans-epithelial electrical conductance ( $G_t$ ,  $\text{mS}/\text{cm}^2$ )  
208 was obtained using the Ohm law by the voltage deviation when the tissue was current  
209 pulsed with  $\pm 5 \mu\text{A}$ .

210 Paracellular permeability to fluorescein isothiocyanate (FITC)-dextran 4000 (FD4, Sigma) was  
211 determined during a 100-min period in Ussing chambers. Soon after tissue mounting ( $t_0$ ),  
212 FD4 was added to the chamber mucosal side at the final concentration of 0.250 mg/mL.  
213 Serosal samples were collected at  $t_0$  and after 100 min. To test for tissue viability at the end  
214 of the experiment, carbachol (CCh,  $10^{-4}$  M) was applied at the serosal side verifying the  
215 activation of the calcium-dependent chloride secretion by the  $I_{sc}$  increase.

216

217 **Biochemical analyses and physiological measurements.** Blood glucose concentration was  
218 determined with an Accu-Chek<sup>®</sup> glucometer (Roche Diagnostics, Meylan, France). Plasma  
219 triglyceride concentrations were determined by colorimetric enzymatic methods using a  
220 commercial kit adapted for use in a 96-well microplate reader (Molecular Devices, Saint-  
221 Grégoire, France), and obtained from Randox (Roissy, France)<sup>(34, 35)</sup>. Plasma insulin was  
222 determined using enzyme-linked immuno-assay (Mouse insulin ELISA, Mercodia, Paris,  
223 France). Homeostasis model assesement of insulin resistance (HOMA-IR) index was  
224 calculated using the formula: [fasting insulin (pmol/L) x fasting glucose (mmol/L)]/22.5.

225

226 **Sphingolipidomics.** SL were extracted from feces, jejunum and colon as described previously  
227<sup>(36)</sup>. A volume of 500  $\mu\text{L}$  isopropanol:hexane:water (55:20:25, v/v) and 10  $\mu\text{L}$  standard mix  
228 [0.01 nmol of C12-Cer (d18:1-h12:0), 0.1 nmol of C12-GluCer (d18:1-h12:0) and 0.2 nmol of  
229 ganglioside (GM1)] were added to material and ground using a Polytron homogenizer. The

230 plunger was rinsed with 500  $\mu$ L of extraction solvent and the sample incubated at 60°C for  
231 15 min. After centrifugation at 4000 rpm for 5 min at room temperature, the supernatant  
232 was recovered and the pellet extracted once more with 1 mL of solvent. Supernatants were  
233 combined and dried with a speed Vac. Then the samples were incubated at 50°C for 1 h with  
234 500  $\mu$ L of 33% methylamine solution in ethanol-water (7:3) and dried under nitrogen and  
235 resuspended by sonication in 100  $\mu$ L of tetrahydrofuran-methanol-water (2:1:2) containing  
236 0.1% formic acid and filtrated prior to analysis by liquid chromatography coupled to mass  
237 spectrometry (UPLC- MS/MS). UPLC- MS/MS analyses were carried out on a Waters Acquity  
238 UPLC system coupled to a Waters Xevo tandem quadrupole mass spectrometer equipped  
239 with an ESI source (Waters, Milford, MA, USA). Chromatographic conditions, mass  
240 spectrometric parameters, and multiple reaction monitoring (MRM) methods were defined  
241 as described previously<sup>(29)</sup>.

242

243 **Gene expression.** Total RNA was extracted from EAT and colon samples using Trizol reagent  
244 (Invitrogen, Carlsbad, CA, USA). qRT-PCR was performed with mouse-specific primers  
245 (Eurogentec, Angers, France) to quantify mRNA level of the following genes : interleukin-6  
246 (*Il-6*), interleukin-1 $\beta$  (*Il-1 $\beta$* ) interleukin-10 (*Il-10*) and tumor necrosis factor- $\alpha$  (*Tnf- $\alpha$* ) in both  
247 EAT and colon, plasminogen activator inhibitor-1 (*Pai-1*) and monocyte chemoattractant  
248 protein-1 (*Mcp-1*) in EAT, and claudin 1 (*Cldn1*) and zonula occludens (*Tjp1*) in the colon.  
249 After cDNA synthesis from mRNA using High Capacity cDNA Reverse Transcription Kit  
250 (ThermoFisher-Life Technologies, Les Ulis, France), Real-Time PCR was performed  
251 subsequently on cDNA using the power SYBR Green PCR master mix and StepOne Real-Time  
252 PCR system (ThermoFisher-Life Technologies, Les Ulis, France). cDNA samples were assayed

253 in triplicate and gene expression levels for each sample were normalized relative to  
254 hypoxanthine-guanine phosphoribosyltransferase gene (*Hprt*) with  $2^{-\Delta\Delta Ct}$  calculation.

255

256 **Statistical analyses.** Data are reported as means  $\pm$  standard deviations. They were analysed  
257 using the XLSTAT application (Addinsoft, Paris, France). Significance level was set at  $P < 0.05$ .  
258 The effects of energy level (HC vs NC) and of camelina meal (HC-Con vs HC-CamC16/C24)  
259 were tested using a 2-way ANOVA. When diet effect was significant, differences between  
260 means were tested for significance using the *post-hoc* Tukey procedure.

261

## 262 **RESULTS.**

263 **Production of Camelina seeds with different sphingolipid contents.** The high expression of  
264 the C16 specific Ceramide synthase LOH2 from *Arabidopsis* in *Camelina sativa* led to seeds  
265 with opposite sphingolipid profile (**Supplemental Figure 1**). Camelina seeds and meals (cake  
266 fraction from seeds) from commercial cultivar Céline (CamC24) presented characteristic  
267 sphingolipid profile with high levels of NH<sub>2</sub>GIPC almost exclusively with very long chain FA  
268 (C24). Conversely, the LOH2 expressing line LOH2<sup>Y</sup> (CamC16) accumulated almost exclusively  
269 C16 NH<sub>2</sub>GIPC albeit the levels of total sphingolipids remained similar to CamC24. C16 GluCer  
270 was also increased and C24 GluCer strongly decreased in CamC16 (**Supplemental Table 2**). A  
271 similar trend was also observed for Cer and hCer but at a much lower scale. The most  
272 abundant LCB in seeds were t18:0 and t18:1 in both lines even if d18:1 and d18:0 were  
273 increased in LOH2<sup>Y</sup> due to the accumulation of C16 NH<sub>2</sub>GIPC and GluCer. The accumulation  
274 of C16 SL had a weak impact on plant fitness with a slight delay of germination and slower  
275 early growth rate as well as a lower seed yield and weight for LOH2<sup>Y</sup> (data not shown).

276

277 **Body weight and associated parameters.** During the 5 wk of MetS induction, all mice gained  
278 weight, but to a different extent (**Figure 1**). After 5 wk on the experimental diets, mice on  
279 the HC-Con diet exhibited a higher weight gain ( $8.8\pm 1.2$ g) than mice of the NC group, which  
280 gained  $3.5\pm 1.1$  g only (**Supplemental Table 3**). In both HC-Cam groups, body weight gain, as  
281 well as body weight after 2, 3 and 5 weeks on their respective diets, did not differ  
282 significantly from the NC group, but were significantly lower than in the HC-Con group  
283 (**Figure 1 and Supplemental Table 3**). Food intake (as kcal/d) tended to parallel body weight,  
284 and was the highest in the HC-Con group after 6 d and 4 wk, whereas there was no  
285 difference between groups at both times when energy intake was adjusted for body weight  
286 (**Supplemental Table 3**). Apparent digestibility (% intake of dry matter that was not found in  
287 feces) was equivalent after 6 d or 4 wk on the same experimental diets. After 6 d, it was the  
288 lowest in the NC group, intermediary in the HC-Con group and the highest in the HC-CamC24  
289 and HC-CamC16 groups, whereas after 4 wk, it remained the highest in the HC-CamC24  
290 group only (**Supplemental Table 3**).

291

292 **Body composition.** After 3 wk on the experimental diets, the lean mass was the same in all  
293 groups, whereas the fat mass (absolute and relative to body weight) was as expected higher  
294 in the three HC groups than in the NC group, without significant effect of the camelina meals  
295 (**Table 2**). After 5 wk, mice of the HC-Con group were significantly heavier than those of the  
296 NC group whereas mice of both HC-Cam groups showed intermediate body weight (**Figure 1**  
297 and **Table 2**). Similarly, when compared to the NC group, adiposity (absolute and relative  
298 weight of the EAT) was globally increased in the three HC groups, but to a lower extent in  
299 the HC-Cam groups. While liver and small intestine weights were similar in all groups, the

300 weights of the caecum and the colon, as well as of the caecum content, were significantly  
301 lower in the three HC groups.

302

303 **Blood and tissue markers associated with the MetS.** During an OGTT after 3 weeks on the  
304 experimental diets, glucose and insulin plasma concentration increased sharply during 15  
305 min, then returned to fasting values after 120 min in all groups (**Figure 2**). When compared  
306 to the NC group, the HC-Con group exhibited higher fasting glucose and insulin  
307 concentration (t0) and AUC over 120 min, as well as higher **HOMA-IR index** (**Table 3 and**  
308 **Figure 2**). Besides, the increase in glucose concentration between t0 and t30 min, which  
309 takes into account the difference in fasting glycemia between groups ( $\Delta$  glucose), was two-  
310 fold higher in the HC-Con group than in the NC group. In both HC-Cam groups, fasting  
311 glucose concentration and AUC over 120 min were similar to those of the HC-Con group, and  
312 higher than in the NC-Con group, whereas insulin AUC and HOMA did not differ from the NC-  
313 Con group and were therefore lower than in the HC-group. Interestingly, insulin fasting  
314 plasma concentration in HC-CamC16 mice did not differ from the NC mice and was  
315 significantly lower than in the HC-Con mice, which was not the case in mice HC-CamC24  
316 mice. In the two HC-Cam groups,  $\Delta$  glucose between t30 and t0 of the OGTT was  
317 intermediary between NC- and HC-Con groups.

318 At the end of the experiment, after 5 weeks on the experimental diets, fasting glucose  
319 concentrations did not differ from those after 3 weeks, remaining higher in the three HC  
320 groups than in the NC group (**Table 3**). Fasting triglyceridemia was identical in NC- and HC-  
321 Con groups, but was surprisingly 2-fold lower in the 2 HC-Cam groups. Compared to the NC-  
322 Con group, fasting cholesterolemia was higher in all the HC groups but only significantly in  
323 both HC-Cam groups.

324 Transcript levels of a few inflammatory and vascular markers were higher in mice fed the  
325 HC diets: *Mcp-1* and *Pai-1* in the adipose tissue ( $P = 0.011$  and  $0.002$ , respectively) and *Il-1  $\beta$*   
326 in the colon ( $P = 0.039$ ). However, according to the *post-hoc* Tukey test, and as compared to  
327 the NC group, *Mcp-1* and *Il-1 $\beta$*  were significantly higher in the HC-Con group  
328 only, and *Pai-1* in the HC-Cam groups only (**Table 4**). Other mRNA levels of inflammatory  
329 markers (*Il-6*, *Il-1 $\beta$* , *Il-10* and *Tnf- $\alpha$*  in the adipose tissue and *Il-6*, *Il-10*, *Tnf- $\alpha$*  in the colon) did  
330 not differ between groups, neither did those of the tight junction protein encoding genes  
331 *Tjp1* and *Cldn1* in the colon (data not shown).

332

333 **Colon epithelial barrier and permeability.** Measurement of electrical parameters in Ussing  
334 chambers was performed on proximal colon (**Table 5**). There was no difference in the FD4  
335 permeability within the diet groups, which indicated that paracellular pathway of the gut  
336 barrier function in the colon was not altered (data not shown). The colon transepithelial  
337 voltage ( $V_t$ ), which is usually negative at the colonocyte luminal side, was more negative in  
338 the 3 HC groups than in the control NC group, this effect being significantly less pronounced  
339 in the HC-CamC16 group. Conversely, the short-circuit current ( $I_{sc}$ ) was higher in the three  
340 HC groups, with no difference between them. Trans-epithelial conductance ( $G_t$ ) in the three  
341 HC groups did not differ from that in the NC group, however the HC-CamC16 and the HC-  
342 Cam24 groups showed the highest and lowest values respectively.

343

344 **SL intake, excretion and tissue profile.** Apparent  $\text{NH}_2\text{GIPC}$  digestibility (**Table 6**) was  
345 calculated after 4 wk of experimental diets, using the *in vivo* measurement of food intake  
346 and fecal excretion and the analysis of complete plant sphingolipidomic profiles of diets  
347 (**Table 1**) and feces (data not shown). Since  $\text{NH}_2\text{GIPC}$  accounted for nearly 80% of total SL in



348 HC-CamC16 and HC-CamC24 diets, intake and excretion were calculated in this fraction only.  
349 Mean individual NH<sub>2</sub>GIPC dietary intake, expressed as absolute amounts, grossly reflected  
350 their dietary profile. It was very low in the HC-Con group, much higher in the NC group (over  
351 40 fold increase), and even further increased in both HC-Cam groups by over 80 fold, with no  
352 significant difference between the two groups. In contrast, NH<sub>2</sub>GIPC excretion differed  
353 markedly between the HC-Cam groups. Excretion rate of NH<sub>2</sub>GIPC in the HC-CamC16 group  
354 was 2.5-fold higher than that in the HC-CamC24 group. Consequently, the apparent  
355 digestibility of dietary NH<sub>2</sub>GIPC was significantly lower (80%) in the HC-CamC16 than in the  
356 three other groups (87-94%).

357 Concentration of the most abundant plant SL (NH<sub>2</sub>GIPC and GluCer with C16 and C24 FA)  
358 was determined in the jejunum and colon walls (**Table 7**). Jejunum and colon of the NC  
359 group contained similar amount of C24-NH<sub>2</sub>GIPC and C24-GluCer, while the latter was a  
360 minor component of the diet. Jejunum and colon of the HC-Con mice were nearly devoid of  
361 phytoSL, as expected from their low level in the HC-Con diet. On the contrary, plant NH<sub>2</sub>GIPC  
362 and GluCer were found in the intestine on mice fed with the camelina meals. As expected  
363 C24-SL were the most prominent SL in the HC-CamC24 group, while C16-SL was the most  
364 abundant in the HC-CamC16 group, with NH<sub>2</sub>GIPC being the most abundant SL in both  
365 groups. Tissue content of the various SL species was lower in the colon than in the jejunum,  
366 however small levels of plant NH<sub>2</sub>GIPC were still present in the colon. Finally, the total  
367 concentration of SL (GluCer + NH<sub>2</sub>GIPC) in the intestine of HC-CamC16 mice was  
368 approximately 2-fold higher in the jejunum (12.5 nmol/g) and in 5-fold higher in the colon  
369 (2.14 nmol/g) than in HC-CamC24 mice (6.40 and 0.40 nmol/g in the jejunum and colon,  
370 respectively). Interestingly, while C24-GluCer ratio between colon and jejunum was similar in  
371 the two HC-Cam groups (0.38 vs 0.41), this ratio was much lower in the HC-CamC24 group

372 than in the HC-Cam16 group for C24-NH<sub>2</sub>GIPC (0.05 vs 0.26) and even lower in the HC-  
373 Cam16 group for C16-NH<sub>2</sub>GIPC (0.05 vs 0.16).

374

## 375 **DISCUSSION.**

376 **Digestive bioavailability of camelina SL.** In most *in vivo* studies aiming to highlight the  
377 mechanisms involved in potentially beneficial effects of plant SL at the systemic level, a  
378 dramatic gap remains concerning the bioavailability of plant SL when provided in the diet.  
379 Both animal and plant SL are hydrolysed into LCB, FA, and the polar head group in the small  
380 intestine, then eventually absorbed, reesterified, and secreted into the lymph <sup>(37-40)</sup>. As  
381 regards phytoSL, it is needed to document to what extent they are digested then absorbed,  
382 in which form they are transported and made available to various tissues, and which  
383 molecular species are stored in various body compartments.

384 To our knowledge, the present study quantifies, for the first time, intestinal digestibility  
385 of a major phytoSL (NH<sub>2</sub>GIPC, accounting for nearly 80% of total SL in the HC-Cam diets)  
386 when provided as a dietary component. Camelina NH<sub>2</sub>GIPC in the two HC-Cam diets  
387 exhibited the same LCB profile, and only differed in their FA **length** (mainly C24 in the  
388 CamC24 meal and C16 in the CamC16 meal). Although apparent digestibility of dietary  
389 NH<sub>2</sub>GIPC was high, it was lower in the HC-CamC16 group, which could be accounted for by a  
390 higher fecal excretion. However, the higher NH<sub>2</sub>GIPC content in the gut wall **of** the HC-  
391 Camc16 fed group, suggests some metabolic specificity during reesterification and excretion  
392 into the lymph(**Table 7**). **Besides, beyond this demonstration of the NH<sub>2</sub>GIPC availability at**  
393 **the digestive level, NH<sub>2</sub>GIPC-containing SL, or their metabolites, have to be sought in other**  
394 **body compartments, this lack of information being a limitation of the present study.**

395

396 **Effects of the camelina meal on the early markers of the MetS.** Plant SL have been shown  
397 to exert beneficial effects on some risk factors associated with the MetS, such as altered  
398 glucose homeostasis, abnormal lipid profile, and low-grade chronic inflammation. In the  
399 present study, we used our mouse model of the early steps of the MetS to explore the  
400 effects of dietary plant SL provided by camelina meal in a hypercaloric diet <sup>(41)</sup>. As expected  
401 from this model, after 5 wk on a hypercaloric diet rich in saturated FA and sucrose (HC-Con  
402 group), mice exhibited (as compared to those on a normocaloric diet, NC-group) an increase  
403 in body weight and adiposity (**Table 2** and **Figure 1**), and in fasting glycemia (**Table 4**). After  
404 only 3 wk, these alterations were already detectable and were accompanied by higher  
405 values of insulinemia and HOMA-IR index (**Table 3**), and of glucose and insulin postprandial  
406 AUC (**Figure 2**). These findings are consistent with data obtained in mice fed a HC diet rich in  
407 saturated FA <sup>(42)</sup>.

408 When SL was provided as camelina meal in the HC diet (HC-CamC24 and -C16 groups),  
409 body weight gain and adiposity were reduced, but not the lean mass (**Figure 1** and **Table 2**).  
410 This specific effect of camelina meals on adiposity was not accounted for by a lower food  
411 intake, since it was the same in all groups after 6 d and 4 wk when normalized for body  
412 weight. Whether this effect is due to the presence of SL in the diet is questionable, since no  
413 significant effect of phytoSL was reported for body weight, fat mass or body mass index in  
414 previous studies <sup>(14-17, 43, 44)</sup>. In our study, the presence of other components of the camelina  
415 meal, such as fibers, may be responsible for a lower nutrient absorption, and subsequent  
416 bioavailability, lowering body storage of lipids, either exogenous (dietary) or endogenous (*de*  
417 *novo* synthesised). However, a specific effect of phytoSL may not be precluded, since a very  
418 recent study showed that mice fed a high-fat diet supplemented with milk polar lipids  
419 containing 25% SL gained less weight than mice on the high-fat diet alone <sup>(45)</sup>.

420 In parallel, in mice fed by either camelina meal, fasting insulinemia and HOMA-IR index  
421 were normalized, **as well as insulinemia AUC during an OGTT**, and triglyceridemia decreased  
422 **(Table 3 and Figure 2)**. These findings are grossly consistent with previous studies using  
423 purified SL or LCB in rodent mice models exhibiting features of the MetS or in human  
424 subjects with a MetS. Indeed, various SL or LCB decreased triglyceridemia in mice or sand  
425 rats on a hypercaloric diet <sup>(14, 20)</sup> whereas phytosphingosine decreased glycemia in subjects  
426 with a MetS <sup>(15)</sup> and improved glucose homeostasis in human subjects with a MetS and  
427 various rodent models, <sup>(15-19)</sup>. **In contrast, the present study showed no effect on**  
428 **cholesterolemia, which is inconsistent with previous studies that repeatedly reported a**  
429 **decrease in plasma total, LDL, or non-HDL cholesterol in various rodent models and in**  
430 **subjects with a MetS <sup>(14, 15, 17, 20)</sup>**. One originality of our short-term study is the demonstration  
431 that, when focusing on the onset of the MetS, **an early alteration of glucose homeostasis, as**  
432 **demonstrated by insulin resistance occurrence both at the fasting state and during an OGTT,**  
433 may be counteracted by a phytoSL-rich matrix after only 3 weeks on the experimental diets.

434 The mechanisms by which dietary SL may exert systemic effects remain largely  
435 speculative. First, in response to various SL or LCB, a decrease in the postprandial absorption  
436 of dietary triglycerides and cholesterol has been suggested, and would explain the  
437 downstream effects on lipid metabolism at the hepatic or plasma level <sup>(14, 43)</sup>. Second, gene  
438 regulation by SL or LCB, including activation of various PPARs, and resulting in beneficial  
439 effects on insulin sensitivity, glucose tolerance and lipid metabolism have been also  
440 demonstrated <sup>(17, 20, 43)</sup>. Finally, it has been recently shown that animal SL may affect gut  
441 microbiota in mice in a way that would limit some detrimental effects of HF diets <sup>(45, 46)</sup>. All  
442 these mechanisms, which remain to be investigated in our model, would contribute **to lower**  
443 **adiposity and slower insulin resistance in mice fed the HC-Cam diets (Table 2)**.

444 In response to a diet rich in saturated FA and sucrose, the increased adipose tissue often  
445 features an inflammatory phenotype <sup>(4)</sup>. In the present study that targeted the initial steps of  
446 the MetS, there was no evidence that gene expression of pro-inflammatory cytokines was  
447 enhanced in the adipose tissue, despite an increased adiposity, and providing SL-rich  
448 camelina meal had no significant effect. Gene expression of two others inflammatory  
449 markers, *Mcp-1* and *Pai-1*, was enhanced in response to the HC diet (HC-Con group).  
450 Attenuation of *Mcp-1* mRNA level may be related to the lower adiposity of mice on both HC-  
451 Cam diets, whereas the reason why the HC-Cam diets aggravated the mRNA level of *Pai-1*,  
452 remains to be investigated.

453 To our knowledge, the present study, provides the first evidence that a mixture of natural  
454 plant SL, essentially in the form of NH<sub>2</sub>GIPC, and provided in their original matrix, **exerted**  
455 **some beneficial effects during the MetS onset.** However, the role of other camelina meal  
456 components, such as **phospholipids**, polyphenols or specific fibers cannot be excluded <sup>(47, 48)</sup>.

457

458 **Effects of the camelina meal on the intestine wall.** When compared to the NC group, the  
459 HC-Con diet enhanced a few inflammation markers in the colon and the adipose tissue  
460 (**Table 4**). In contrast, in mice fed the camelina meals, mRNA levels of *Mcp-1* in the adipose  
461 tissue and of *Il-1β* in the colon did not differ from those in the NC group (**Table 4**). The role  
462 of SL in inflammatory processes is still in debate, but a few studies support the hypothesis  
463 that dietary phytoSL (as maize GluCer) or animal SL (as sphingomyelin) alleviate gut  
464 inflammation in rodent models <sup>(23-28)</sup>. How plant SL may improve intestinal inflammation  
465 remains nonetheless highly speculative. A study using Caco-2 cells suggested that SL may  
466 interact with epithelial cells without being absorbed. In these *in vitro* conditions, plant  
467 GluCer remained at the cell surface, but decreased LPS-induced production of inflammatory

468 cytokines, maybe by affecting the interactions between LPS and its TLR at the cell surface <sup>(28)</sup>.  
469 Similar interactions with non-digested plant SL or their metabolites may contribute *in vivo* to  
470 modulate the inflammatory status of the intestine wall. The intestinal microbiota is likely to  
471 contribute to these interactions, since it is able to metabolize animal SL, which would  
472 contribute to regulate cytokine production <sup>(24, 49)</sup>.

473 Interestingly, epithelial integrity of the colon was specifically modified by the HC-CamC16  
474 diet, as demonstrated by its effects on transepithelial voltage ( $V_t$ ) and epithelial conductance  
475 ( $G_t$ ) (Table 5).  $V_t$  describes the unidirectional transport of sodium from the luminal to the  
476 serosal side of the epithelium. This potential difference is usually negative at the colonocyte  
477 luminal side, and was even more negative with HC diets. This effect of HC-diets reflects an  
478 increase in the driving force of the colonocytes to allow the sodium, chloride and water  
479 absorption from the colon lumen, and therefore a loss of permeability. This decrease in  $V_t$   
480 may be related to the high fat content of the diet, known to alter electrical parameters of  
481 transcellular barrier function <sup>(42, 50, 51)</sup>. This damage was attenuated in mice given the diet  
482 containing camelina SL rich in C16 FA (HC-CamC16).  $V_t$  increase in HC-Camc16 mice was also  
483 associated with higher epithelial conductance ( $G_t$ ) which was not due to a loss of epithelial  
484 permeability, at least via the paracellular pathway, because it was not accompanied by an  
485 increase in the apical-to-basal flux of the paracellular marker FD4 in any group. The absence  
486 of dietary effects on the gene expression of two tight junction proteins, claudin 1 (*Cldn1*) and  
487 zonula occludens (*Tjp1*), confirms that the paracellular permeability was not affected by any  
488 of the HC diets. Rather, we suggest that, in the colon of the HC-CamC16 mice, this increased  
489  $G_t$  may reflect a compensatory mechanism that counteracts the increase of actively  
490 transported ions (as evidenced by the higher short-circuit current  $-I_c$  in all HC groups) by  
491 increasing passive movement of ions. This would explain the lower value of  $V_t$  in the HC-

492 CamC16 group. Nevertheless, further investigations would be needed to determine the  
493 precise mechanisms involved in the action of camelina SL (native or digested products) on  
494 activity and/or expression of colon transporters and exchangers that ensured colon barrier  
495 integrity and flux. Yet, it can be concluded from the present study than differences in the FA  
496 profile of dietary plant SL, and particularly the enrichment of C16 FA in the experimental  
497 LOH2<sup>Y</sup> line (to the detriment of C24 FA in the commercial Céline cultivar) modulate the  
498 deleterious effects of a high-fat diet on colon epithelial barrier function, and more  
499 specifically on transepithelial permeability.

500

501 In conclusion, phytoSL provided in a plant matrix **delays** the onset of the MetS, by  
502 reducing adiposity and insulin resistance. Involved mechanisms at the intestinal and  
503 systemic levels remain mostly speculative at this initial stage, but it may be hypothesized  
504 **that some** of the effects observed, including on the adipose tissue and blood parameters,  
505 results from an impact of phytoSL or their metabolites at the intestinal level. Moreover,  
506 some of these effects are modulated by the FA length of the SL, since they are sometimes  
507 more pronounced in presence of C16-NH<sub>2</sub>GIPC. More researchs are required to uncover the  
508 importance of FA length in the interactions between phytoSL, the intestinal wall, and  
509 systemic effects. In this context, interactions of phytoSL and their metabolites with the  
510 microbiota may be a promising avenue of investigation.

511

## 512 **Acknowledgements**

513 The authors acknowledge the valuable contribution of Célia Carbonne, MSc student in UMR  
514 Physiologie de la Nutrition et du Comportement Alimentaire (PNCA), who contributed to the  
515 running of the study, and of Morgane Dufay (UMR PNCA) for animal care and help with

516 dissection and sampling. They thank Ophélie Dhumez (UMR Modélisation systémique  
517 Appliquée aux Ruminants) for the determination of nutrient composition of the camelina  
518 meals.

519

520 **Funding:** This study was funded by Scientific direction and valorisation of AgroParisTech  
521 (2015 incitative call, NUTRICAM project). It has benefited from a French State grant (LabEx  
522 Saclay Plant Sciences-SPS, ref. ANR-10-LABX-0040-SPS), managed by the French National  
523 Research Agency under an "Investments for the Future" program (ref. ANR-11-IDEX-0003-  
524 02).

525

#### 526 **Supporting information.**

527 Supplemental Table 1. Composition and nutritional values of the experimental diets.

528 Supplemental Table 2. SL composition of the camelina meals (nmol/g)

529 Supplemental Table 3. Body weight gain and food intake

530 Supplemental Figure 1. NH<sub>2</sub>GIPCs and GICers profiles in *Camelina sativa* seeds from the  
531 commercial Céline cultivar (CamC24) and from the LOH2<sup>Y</sup> line (CamC16).

532

#### 533 **References.**

534 1. Alberti, K. G.; Eckel, R. H.; Grundy, S. M.; Zimmet, P. Z.; Cleeman, J. I.; Donato, K. A.; Fruchart,  
535 J. C.; James, W. P.; Loria, C. M.; Smith, S. C., Jr., Harmonizing the metabolic syndrome: a joint interim  
536 statement of the International Diabetes Federation Task Force on Epidemiology and Prevention;  
537 National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;  
538 International Atherosclerosis Society; and International Association for the Study of Obesity.  
539 *Circulation* **2009**, *120*, 1640-5.



- 540 2. Cornier, M. A.; Dabelea, D.; Hernandez, T. L.; Lindstrom, R. C.; Steig, A. J.; Stob, N. R.; Van  
541 Pelt, R. E.; Wang, H.; Eckel, R. H., The metabolic syndrome. *Endocr Rev* **2008**, *29*, 777-822.
- 542 3. Araujo, J. R.; Tomas, J.; Brenner, C.; Sansonetti, P. J., Impact of high-fat diet on the intestinal  
543 microbiota and small intestinal physiology before and after the onset of obesity. *Biochimie* **2017**,  
544 *141*, 97-106.
- 545 4. Dandona, P.; Ghanim, H.; Chaudhuri, A.; Dhindsa, S.; Kim, S. S., Macronutrient intake induces  
546 oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance.  
547 *Experimental & molecular medicine* **2010**, *42*, 245-53.
- 548 5. Tremaroli, V.; Backhed, F., Functional interactions between the gut microbiota and host  
549 metabolism. *Nature* **2012**, *489*, 242-9.
- 550 6. Ji, Y.; Sakata, Y.; Tso, P., Nutrient-induced inflammation in the intestine. *Curr Opin Clin Nutr*  
551 *Metab Care* **2011**, *14*, 315-21.
- 552 7. Cani, P. D.; Bibiloni, R.; Knauf, C.; Waget, A.; Neyrinck, A. M.; Delzenne, N. M.; Burcelin, R.,  
553 Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-  
554 induced obesity and diabetes in mice. *Diabetes* **2008**, *57*, 1470-81.
- 555 8. Minihane, A. M.; Vinoy, S.; Russell, W. R.; Baka, A.; Roche, H. M.; Tuohy, K. M.; Teeling, J. L.;  
556 Blaak, E. E.; Fenech, M.; Vauzour, D.; McArdle, H. J.; Kremer, B. H.; Sterkman, L.; Vafeiadou, K.;  
557 Benedetti, M. M.; Williams, C. M.; Calder, P. C., Low-grade inflammation, diet composition and  
558 health: current research evidence and its translation. *Br J Nutr* **2015**, *114*, 999-1012.
- 559 9. Nagpal, R.; Kumar, M.; Yadav, A. K.; Hemalatha, R.; Yadav, H.; Marotta, F.; Yamashiro, Y., Gut  
560 microbiota in health and disease: an overview focused on metabolic inflammation. *Beneficial*  
561 *microbes* **2016**, *7*, 181-94.
- 562 10. Berkey, R.; Bendigeri, D.; Xiao, S., Sphingolipids and plant defense/disease: the "death"  
563 connection and beyond. *Frontiers in plant science* **2012**, *3*, 68.
- 564 11. Lipina, C.; Hundal, H. S., Sphingolipids: agents provocateurs in the pathogenesis of insulin  
565 resistance. *Diabetologia* **2011**, *54*, 1596-607.

- 566 12. Langeveld, M.; Aerts, J. M., Glycosphingolipids and insulin resistance. *Prog Lipid Res* **2009**, *48*,  
567 196-205.
- 568 13. Park, J. W.; Park, W. J.; Kuperman, Y.; Boura-Halfon, S.; Pewzner-Jung, Y.; Futerman, A. H.,  
569 Ablation of very long acyl chain sphingolipids causes hepatic insulin resistance in mice due to altered  
570 detergent-resistant membranes. *Hepatology* **2013**, *57*, 525-32.
- 571 14. Duivenvoorden, I.; Voshol, P. J.; Rensen, P. C.; van Duyvenvoorde, W.; Romijn, J. A.; Emeis, J.  
572 J.; Havekes, L. M.; Nieuwenhuizen, W. F., Dietary sphingolipids lower plasma cholesterol and  
573 triacylglycerol and prevent liver steatosis in APOE\*3Leiden mice. *Am J Clin Nutr* **2006**, *84*, 312-21.
- 574 15. Snel, M.; Sleddering, M. A.; Pijl, H.; Nieuwenhuizen, W. F.; Frolich, M.; Havekes, L. M.; Romijn,  
575 J. A.; Jazet, I. M., The effect of dietary phytosphingosine on cholesterol levels and insulin sensitivity in  
576 subjects with the metabolic syndrome. *Eur J Clin Nutr* **2010**, *64*, 419-23.
- 577 16. Murakami, I.; Mitsutake, S.; Kobayashi, N.; Matsuda, J.; Suzuki, A.; Shigyo, T.; Igarashi, Y.,  
578 Improved high-fat diet-induced glucose intolerance by an oral administration of phytosphingosine.  
579 *Bioscience, biotechnology, and biochemistry* **2013**, *77*, 194-7.
- 580 17. Yunoki, K.; Renaguli, M.; Kinoshita, M.; Matsuyama, H.; Mawatari, S.; Fujino, T.; Kodama, Y.;  
581 Sugiyama, M.; Ohnishi, M., Dietary sphingolipids ameliorate disorders of lipid metabolism in Zucker  
582 fatty rats. *J Agric Food Chem* **2010**, *58*, 7030-5.
- 583 18. Zigmond, E.; Zangen, S. W.; Pappo, O.; Sklair-Levy, M.; Lalazar, G.; Zolotaryova, L.; Raz, I.; Ilan,  
584 Y., Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic  
585 rat. *Am J Physiol Endocrinol Metab* **2009**, *296*, E72-8.
- 586 19. Lalazar, G.; Zigmond, E.; Weksler-Zangen, S.; Ben Ya'acov, A.; Sklair Levy, M.; Hemed, N.; Raz,  
587 I.; Ilan, Y., Oral Administration of beta-Glucosylceramide for the Treatment of Insulin Resistance and  
588 Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial. *J Med Food* **2017**.
- 589 20. Zigmond, E.; Tayer-Shifman, O.; Lalazar, G.; Ben Ya'acov, A.; Weksler-Zangen, S.; Shasha, D.;  
590 Sklair-Levy, M.; Zolotarov, L.; Shalev, Z.; Kalman, R.; Ziv, E.; Raz, I.; Ilan, Y., beta-glycosphingolipids

591 ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model. *Journal of inflammation*  
592 *research* **2014**, *7*, 151-8.

593 21. Norris, G. H.; Blesso, C. N., Dietary sphingolipids: potential for management of dyslipidemia  
594 and nonalcoholic fatty liver disease. *Nutr Rev* **2017**, *75*, 274-285.

595 22. Zhang, W.; Moritoki, Y.; Tsuneyama, K.; Yang, G. X.; Ilan, Y.; Lian, Z. X.; Gershwin, M. E., Beta-  
596 glucosylceramide ameliorates liver inflammation in murine autoimmune cholangitis. *Clinical and*  
597 *experimental immunology* **2009**, *157*, 359-64.

598 23. Arai, K.; Mizobuchi, Y.; Tokuji, Y.; Aida, K.; Yamashita, S.; Ohnishi, M.; Kinoshita, M., Effects of  
599 Dietary Plant-Origin Glucosylceramide on Bowel Inflammation in DSS-Treated Mice. *J Oleo Sci* **2015**,  
600 *64*, 737-42.

601 24. Bryan, P. F.; Karla, C.; Edgar Alejandro, M. T.; Sara Elva, E. P.; Gemma, F.; Luz, C.,  
602 Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for  
603 Inflammatory Bowel Disease. *Mediators of inflammation* **2016**, *2016*, 9890141.

604 25. Camp, E. R.; Patterson, L. D.; Kester, M.; Voelkel-Johnson, C., Therapeutic implications of  
605 bioactive sphingolipids: A focus on colorectal cancer. *Cancer biology & therapy* **2017**, *18*, 640-650.

606 26. Duan, J.; Sugawara, T.; Sakai, S.; Aida, K.; Hirata, T., Oral glucosylceramide reduces 2,4-  
607 dinitrofluorobenzene induced inflammatory response in mice by reducing TNF-alpha levels and  
608 leukocyte infiltration. *Lipids* **2011**, *46*, 505-12.

609 27. Mazzei, J. C.; Zhou, H.; Brayfield, B. P.; Hontecillas, R.; Bassaganya-Riera, J.; Schmelz, E. M.,  
610 Suppression of intestinal inflammation and inflammation-driven colon cancer in mice by dietary  
611 sphingomyelin: importance of peroxisome proliferator-activated receptor gamma expression. *J Nutr*  
612 *Biochem* **2011**, *22*, 1160-71.

613 28. Yamashita, S.; Sakurai, R.; Hishiki, K.; Aida, K.; Kinoshita, M., Effects of Dietary Plant-origin  
614 Glucosylceramide on Colon Cytokine Contents in DMH-treated Mice. *J Oleo Sci* **2017**, *66*, 157-160.

615 29. Tellier, F.; Maia-Grondard, A.; Schmitz-Afonso, I.; Faure, J. D., Comparative plant  
616 sphingolipidomic reveals specific lipids in seeds and oil. *Phytochemistry* **2014**, *103*, 50-8.

- 617 30. Julie-Galau, S.; Bellec, Y.; Faure, J. D.; Tepfer, M., Evaluation of the potential for interspecific  
618 hybridization between *Camelina sativa* and related wild Brassicaceae in anticipation of field trials of  
619 GM camelina. *Transgenic research* **2014**, *23*, 67-74.
- 620 31. Morineau, C.; Bellec, Y.; Tellier, F.; Gissot, L.; Kelemen, Z.; Nogue, F.; Faure, J. D., Selective  
621 gene dosage by CRISPR-Cas9 genome editing in hexaploid *Camelina sativa*. *Plant biotechnology*  
622 *journal* **2017**, *15*, 729-739.
- 623 32. de Andrade, P. V.; Schmidely, P., Effect of duodenal infusion of trans10,cis12-CLA on milk  
624 performance and milk fatty acid profile in dairy goats fed high or low concentrate diet in combination  
625 with rolled canola seed. *Reprod Nutr Dev* **2006**, *46*, 31-48.
- 626 33. Beaumont, M.; Andriamihaja, M.; Armand, L.; Grauso, M.; Jaffrezic, F.; Laloe, D.; Moroldo,  
627 M.; Davila, A. M.; Tome, D.; Blachier, F.; Lan, A., Epithelial response to a high-protein diet in rat colon.  
628 *BMC Genomics* **2017**, *18*, 116.
- 629 34. Fossati, P.; Prencipe, L., Serum triglycerides determined colorimetrically with an enzyme that  
630 produces hydrogen peroxide. *Clin Chem* **1982**, *28*, 2077-80.
- 631 35. Takayama, M.; Itoh, S.; Nagasaki, T.; Tanimizu, I., A new enzymatic method for determination  
632 of serum choline-containing phospholipids. *Clin Chim Acta* **1977**, *79*, 93-8.
- 633 36. Markham, J. E.; Jaworski, J. G., Rapid measurement of sphingolipids from *Arabidopsis*  
634 *thaliana* by reversed-phase high-performance liquid chromatography coupled to electrospray  
635 ionization tandem mass spectrometry. *Rapid communications in mass spectrometry : RCM* **2007**, *21*,  
636 1304-14.
- 637 37. Fujii, A.; Manabe, Y.; Aida, K.; Tsuduki, T.; Hirata, T.; Sugawara, T., Selective Absorption of  
638 Dietary Sphingoid Bases from the Intestine via Efflux by P-Glycoprotein in Rats. *J Nutr Sci Vitaminol*  
639 *(Tokyo)* **2017**, *63*, 44-50.
- 640 38. Ishikawa, J.; Takada, S.; Hashizume, K.; Takagi, Y.; Hotta, M.; Masukawa, Y.; Kitahara, T.;  
641 Mizutani, Y.; Igarashi, Y., Dietary glucosylceramide is absorbed into the lymph and increases levels of  
642 epidermal sphingolipids. *Journal of dermatological science* **2009**, *56*, 220-2.

- 643 39. Sugawara, T.; Kinoshita, M.; Ohnishi, M.; Nagata, J.; Saito, M., Digestion of maize  
644 sphingolipids in rats and uptake of sphingadienine by Caco-2 cells. *J Nutr* **2003**, *133*, 2777-82.
- 645 40. Sugawara, T.; Tsuduki, T.; Yano, S.; Hirose, M.; Duan, J.; Aida, K.; Ikeda, I.; Hirata, T., Intestinal  
646 absorption of dietary maize glucosylceramide in lymphatic duct cannulated rats. *J Lipid Res* **2010**, *51*,  
647 1761-9.
- 648 41. Hermier, D.; Guelzim, N.; Martin, P. G.; Huneau, J. F.; Mathe, V.; Quignard-Boulangue, A.;  
649 Lasserre, F.; Mariotti, F., NO synthesis from arginine is favored by alpha-linolenic acid in mice fed a  
650 high-fat diet. *Amino Acids* **2016**, *48*, 2157-68.
- 651 42. Lam, Y. Y.; Ha, C. W.; Hoffmann, J. M.; Oscarsson, J.; Dinudom, A.; Mather, T. J.; Cook, D. I.;  
652 Hunt, N. H.; Caterson, I. D.; Holmes, A. J.; Storlien, L. H., Effects of dietary fat profile on gut  
653 permeability and microbiota and their relationships with metabolic changes in mice. *Obesity (Silver*  
654 *Spring)* **2015**, *23*, 1429-39.
- 655 43. Chung, R. W.; Kamili, A.; Tandy, S.; Weir, J. M.; Gaire, R.; Wong, G.; Meikle, P. J.; Cohn, J. S.;  
656 Rye, K. A., Dietary sphingomyelin lowers hepatic lipid levels and inhibits intestinal cholesterol  
657 absorption in high-fat-fed mice. *PLoS One* **2013**, *8*, e55949.
- 658 44. Lalazar, G.; Zigmond, E.; Weksler-Zangen, S.; Ya'acov, A. B.; Levy, M. S.; Hemed, N.; Raz, I.;  
659 Ilan, Y., Oral Administration of beta-Glucosylceramide for the Treatment of Insulin Resistance and  
660 Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial. *J Med Food* **2017**,  
661 *20*, 458-464.
- 662 45. Milard, M.; Laugerette, F.; Durand, A.; Buisson, C.; Meugnier, E.; Loizon, E.; Louche-Pelissier,  
663 C.; Sauvinet, V.; Garnier, L.; Viel, S.; Bertrand, K.; Joffre, F.; Cheillan, D.; Humbert, L.; Rainteau, D.;  
664 Plaisancie, P.; Bindels, L. B.; Neyrinck, A. M.; Delzenne, N. M.; Michalski, M. C., Milk Polar Lipids in a  
665 High-Fat Diet Can Prevent Body Weight Gain: Modulated Abundance of Gut Bacteria in Relation with  
666 Fecal Loss of Specific Fatty Acids. *Mol Nutr Food Res* **2019**, *63*, e1801078.
- 667 46. Norris, G. H.; Jiang, C.; Ryan, J.; Porter, C. M.; Blesso, C. N., Milk sphingomyelin improves lipid  
668 metabolism and alters gut microbiota in high fat diet-fed mice. *J Nutr Biochem* **2016**, *30*, 93-101.

- 669 47. Chaturvedi, S.; Bhattacharya, A.; Khare, S. K.; Kaushik, G., Camelina sativa: An Emerging  
670 Biofuel Crop. In *Handbook of Environmental Materials Management*, Hussain, C. M., Ed. Springer  
671 International Publishing: Cham, 2018; pp 1-38.
- 672 48. Smit, M. N.; Beltranena, E., Effects of feeding camelina cake to weaned pigs on safety,  
673 growth performance, and fatty acid composition of pork. *Journal of animal science* **2017**, *95*, 2496-  
674 2508.
- 675 49. Norris, G. H.; Blesso, C. N., Dietary and Endogenous Sphingolipid Metabolism in Chronic  
676 Inflammation. *Nutrients* **2017**, *9*.
- 677 50. Muller, V. M.; Zietek, T.; Rohm, F.; Fiamoncini, J.; Lagkouvardos, I.; Haller, D.; Clavel, T.;  
678 Daniel, H., Gut barrier impairment by high-fat diet in mice depends on housing conditions. *Mol Nutr*  
679 *Food Res* **2016**, *60*, 897-908.
- 680 51. Tomas, J.; Mulet, C.; Saffarian, A.; Cavin, J. B.; Ducroc, R.; Regnault, B.; Kun Tan, C.; Duszka,  
681 K.; Burcelin, R.; Wahli, W.; Sansonetti, P. J.; Pedron, T., High-fat diet modifies the PPAR-gamma  
682 pathway leading to disruption of microbial and physiological ecosystem in murine small intestine.  
683 *Proc Natl Acad Sci U S A* **2016**, *113*, E5934-E5943.

684

685

686

687 **Table 1. SL composition of the experimental diets (nmol/g).**

688		NC	HC-Con	HC-CamC24	HC-CamC16
689	Total Cer	125	54	61	70
690	C16-Cer	11.4	8.36	9.39	14.7
691	C24-Cer	43.7	14.3	16.6	17.5
692	Total hCer	107	34	44	53
693	C16-hCer	4.99	5.61	5.84	10.9
694	C24-hCer	45.2	13.0	18.1	19.7
695	Total GluCer	20	0.44	10.6	7.6
696	C16-GluCer	6.26	0.14	1.53	4.3
697	C24-GluCer	8.30	0.20	7.08	2.4
698	Total NH <sub>2</sub> GIPC	222	5.31	444	463
699	C16-NH <sub>2</sub> GIPC	0.82	0.38	6.71	421
700	C24-NH <sub>2</sub> GIPC	98.9	2.61	363	33
701	Total SL	473	94.0	560	593
702	C16-SL	23.4	14.3	23.5	450
703	C24-SL	194	30.0	404	72.6
704	Total NH <sub>2</sub> GIPC (% of total SL)	46.9	5.6	79.3	78.1
705	C16-NH <sub>2</sub> GIPC (% of total NH <sub>2</sub> GIPC )	0.37	7.16	1.51	90.9
706	C24-NH <sub>2</sub> GIPC (% of total NH <sub>2</sub> GIPC)	44.5	49.2	81.8	7.1

705

706 NC, normo-caloric; HC, hyper-caloric; Con, control; CamC24, camelina meal C24 (from the  
 707 commercial Céline cultivar rich in C24 fatty acids); CamC16, camelina meal C16 (from the  
 708 experimental LOH2 cultivar rich in C16 fatty acids); hCer, hydroxyceramide; GluCer, glucosyl-  
 709 ceramide; NH<sub>2</sub>GIPC, aminoglycosyl-inositol-phosphoryl-ceramide.

710

711 **Table 2. Body composition after 3 and 5 weeks on the experimental diets**

	NC	HC-Con	HC-CamC24	HC-CamC16	<i>P</i> ANOVA
<i>After 3 weeks</i>					
Body weight (fed state, g)	25.6±2.0 <sup>a</sup>	29.9±2.4 <sup>b</sup>	27.1±1.4 <sup>a</sup>	27.0±1.0 <sup>a</sup>	0.0013
Lean body mass (g)	21.2±1.5 <sup>a</sup>	21.0±0.9 <sup>a</sup>	20.0±1.1 <sup>a</sup>	20.5±0.7 <sup>a</sup>	0.1086
Fat body mass (g)	4.28±0.79 <sup>a</sup>	8.31±1.92 <sup>c</sup>	6.69±1.72 <sup>bc</sup>	6.19±1.07 <sup>ab</sup>	0.0006
Fat body mass (% body weight)	16.7±2.4 <sup>a</sup>	28.1±4.8 <sup>b</sup>	24.9±5.2 <sup>b</sup>	23.1±3.2 <sup>b</sup>	0.0004
<i>After 5 weeks</i>					
Body weight (fasted state, g)	26.7±2.5 <sup>a</sup>	31.5±4.1 <sup>b</sup>	28.6±0.5 <sup>ab</sup>	28.6±1.3 <sup>ab</sup>	0.0148
EAT (mg)	558±117 <sup>a</sup>	1446±520 <sup>b</sup>	911±199 <sup>a</sup>	946±186 <sup>a</sup>	0.0003
EAT (% body weight)	2.08±0.36 <sup>a</sup>	4.48±1.18 <sup>c</sup>	3.19±0.60 <sup>b</sup>	3.29±0.52 <sup>b</sup>	0.0002
Liver (g)	1.18±0.15 <sup>a</sup>	1.16±0.16 <sup>a</sup>	1.07±0.20 <sup>a</sup>	1.05±0.17 <sup>a</sup>	0.4780
Small intestine (mg)	947±96 <sup>a</sup>	836±91 <sup>a</sup>	830±60 <sup>a</sup>	862±84 <sup>a</sup>	0.0546
Caecum (mg)	109±23 <sup>a</sup>	58±33 <sup>b</sup>	69±18 <sup>b</sup>	67±13 <sup>b</sup>	0.0002
Caecum content (mg)	301±76 <sup>a</sup>	157±41 <sup>b</sup>	164±53 <sup>b</sup>	185±31 <sup>b</sup>	<0.0001
Colon (mg)	193±19 <sup>a</sup>	139±25 <sup>b</sup>	132±15 <sup>b</sup>	131±29 <sup>b</sup>	<0.0001
Colon content (mg)	115±17 <sup>a</sup>	79±21 <sup>a</sup>	91±28 <sup>a</sup>	101±34 <sup>a</sup>	0.0968

712 Values are means ± standard deviations for 6 and 9 mice in the NC and the three HC- groups,  
 713 respectively. Mean values within a row, not sharing a same superscript letter, were  
 714 significantly different at *P*<0.05.

715 NC, normo-caloric; HC, hyper-caloric; Con, control; CamC24, camelina meal C24 (from the  
 716 commercial Céline cultivar rich in C24 fatty acids); CamC16, camelina meal C16 (from the  
 717 experimental LOH2 cultivar rich in C16 fatty acids); EAT, epididymal adipose tissue.



718 **Table 3. Blood markers associated with a MetS after 3 weeks (during an OGTT) and 5**  
 719 **weeks on the experimental diets.**

	NC	HC-Con	HC-CamC24	HC-CamC16	<i>P</i> ANOVA
<i>3 weeks</i>					
Glucose t0 (g/L)	1.22±0.10 <sup>a</sup>	1.59±0.13 <sup>b</sup>	1.52±0.14 <sup>b</sup>	1.51±0.13 <sup>b</sup>	<0.0001
Insulin t0 (µg/L)	0.67±0.33 <sup>a</sup>	1.37±0.38 <sup>b</sup>	0.90±0.42 <sup>ab</sup>	0.78±0.33 <sup>a</sup>	0.0035
HOMA-IR index	5.63±2.48 <sup>a</sup>	15.60±5.03 <sup>b</sup>	9.73±4.36 <sup>a</sup>	8.33±3.54 <sup>a</sup>	0.0004
Δ glucose (t30-t0 g/L)	0.59±0.17 <sup>a</sup>	1.41±0.50 <sup>b</sup>	1.22±0.78 <sup>ab</sup>	0.91±0.32 <sup>ab</sup>	0.0261
<i>5 weeks</i>					
Glucose (g/L)	1.18±0.17 <sup>a</sup>	1.60±0.17 <sup>b</sup>	1.58±0.14 <sup>b</sup>	1.55±0.14 <sup>b</sup>	<0.0001
Triglyceride (g/L)	0.69±0.18 <sup>a</sup>	0.60±10 <sup>a</sup>	0.35±0.04 <sup>b</sup>	0.38±0.09 <sup>b</sup>	<0.0001
Cholesterol (g/L)	1.01±0.18 <sup>a</sup>	1.55±0.47 <sup>ab</sup>	1.73±0.32 <sup>b</sup>	1.74±0.19 <sup>b</sup>	0.0088

720

721 Values are means ± standard deviations for 6 and 9 mice in the NC and the three HC- groups,  
 722 respectively. Mean values within a row, not sharing a same superscript letter, were  
 723 significantly different at *P*<0.05.

724 NC, normo-caloric; HC, hyper-caloric; Con, control; CamC24, camelina meal C24 (from the  
 725 commercial Céline cultivar rich in C24 fatty acids); CamC16, camelina meal C16 (from the  
 726 experimental LOH2 cultivar rich in C16 fatty acids).

727 HOMA-IR: homeostasis model assessment of insulin resistance

728

729 **Table 4. Relative gene expression level of some markers of low-grade inflammation.**

730

	NC	HC-Con	HC-CamC24	HC-CamC16	P ANOVA
<u>EAT</u>					
<i>Mcp-1</i>	1.19±0.72 <sup>a</sup>	3.55±2.07 <sup>b</sup>	2.79±1.10 <sup>ab</sup>	2.08±0.77 <sup>ab</sup>	0.0168
<i>Pai-1</i>	1.24±0.81 <sup>a</sup>	2.67±1.02 <sup>ab</sup>	4.12±1.64 <sup>b</sup>	3.17±1.28 <sup>b</sup>	0.0021
<u>Colon</u>					
<i>Il-1β</i>	1.03±0.25 <sup>a</sup>	2.03±1.02 <sup>b</sup>	1.60±0.39 <sup>ab</sup>	1.58±0.44 <sup>ab</sup>	0.0707

731

732 Values are means ± standard deviations for 6 and 8-9 mice in the NC and the three HC-  
 733 groups, respectively. They were calculated according to the  $2^{-\Delta\Delta Ct}$ , where  $\Delta Ct = (Ct \text{ target}$   
 734  $\text{gene} - Ct \text{ HPRT})$  normalized to the NC group. Mean values within a row, not sharing a same  
 735 superscript letter, were significantly different at  $P < 0.05$ .

736 NC, normo-caloric; HC, hyper-caloric; Con, control; CamC24, camelina meal C24 (from the  
 737 commercial Céline cultivar rich in C24 fatty acids); CamC16, camelina meal C16 (from the  
 738 experimental LOH2 cultivar rich in C16 fatty acids).

739

740 **Table 5. Electrical measurement of colon epithelium parameters in Ussing chambers.**

741

	NC	HC-Con	HC-CamC24	HC-CamC16	<i>P</i> ANOVA
$V_t$ (mV)	-2.78±0.15 <sup>a</sup>	-8.45±0.83 <sup>b</sup>	-9.08±1.32 <sup>b</sup>	-5.90±1.30 <sup>c</sup>	<0.0001
$I_{sc}$ ( $\mu$ A/cm <sup>2</sup> )	59±10 <sup>a</sup>	166±17 <sup>b</sup>	149±14 <sup>b</sup>	142±3 <sup>b</sup>	<0.0001
$G_t$ (mS/cm <sup>2</sup> )	16.8±2.2 <sup>ab</sup>	16.5±1.8 <sup>ab</sup>	14.0±2.4 <sup>a</sup>	20.1± 3.3 <sup>b</sup>	0.0396

742

743 Measures were acquired after 45-minutes epithelium equilibration in recording buffer.  $V_t$   
 744 trans-epithelial voltage;  $I_{sc}$  short-circuit current;  $G_t$  trans-epithelial electrical conductance.

745 Values are means  $\pm$  standard deviations for 3-4 mice in each group.

746 Mean values within a row, not sharing a same superscript letter, were significantly different  
 747 at  $P<0.05$ .

748 NC, normo-caloric; HC, hyper-caloric; Con, control; CamC24, camelina meal C24 (from the  
 749 commercial Céline cultivar rich in C24 fatty acids); CamC16, camelina meal C16 (from the  
 750 experimental LOH2 cultivar rich in C16 fatty acids).

751

752 **Table 6. Intake, excretion, and apparent digestibility of NH<sub>2</sub>GIPC after 4 weeks on the**  
 753 **experimental diets.**

	NC	HC-Con	HC-CamC24	HC-CamC16	<i>P</i> ANOVA
NH <sub>2</sub> GIPC Intake (nmol/d)	784±36 <sup>b</sup>	17.7±1.5 <sup>c</sup>	1209±186 <sup>a</sup>	1358±195 <sup>a</sup>	<0.0001
NH <sub>2</sub> -GIPC Excretion (nmol/d)	43.7±10.5 <sup>c</sup>	2.45±0.84 <sup>c</sup>	113±33 <sup>b</sup>	278±48 <sup>a</sup>	<0.0001
NH <sub>2</sub> GIPC Excretion (intake %)	5.74±1.49 <sup>c</sup>	13.73±4.30 <sup>b</sup>	9.40±2.58 <sup>c</sup>	20.33±2.61 <sup>a</sup>	<0.0001
Apparent digestibility (intake %)	94.3±1.5 <sup>a</sup>	86.3±2.6 <sup>b</sup>	90.6±2.6 <sup>ab</sup>	79.7±2.6 <sup>c</sup>	<0.0001

754 Values are means ± standard deviations for 6 and 9 mice in the NC and the three HC- groups,  
 755 respectively. Mean values within a row, not sharing a same superscript letter, were  
 756 significantly different at *P*<0.05.

757 NC, normo-caloric; HC, hyper-caloric; Con, control; CamC24, camelina meal C24 (from the  
 758 commercial Céline cultivar rich in C24 fatty acids); CamC16, camelina meal C16 (from the  
 759 experimental LOH2 cultivar rich in C16 fatty acids).

760

761 **Table 7. Sphingolipid levels in the jejunum and colon (nmol/g).**

762

	NC	HC-Con	HC-CamC24	HC-CamC16	<i>P</i> ANOVA
<b><i>Jejunum</i></b>					
C16 GluCer	0.025 ± 0.021 <sup>ab</sup>	nd	0.009 ± 0.008 <sup>b</sup>	0.027 ± 0.016 <sup>a</sup>	0.0004
C24-GluCer	0.499 ± 0.295 <sup>a</sup>	0.108 ± 0.040 <sup>b</sup>	0.333 ± 0.150 <sup>a</sup>	0.289 ± 0.108 <sup>ab</sup>	0.0006
C16-NH <sub>2</sub> GIPC	nd	nd	0.248 ± 0.122 <sup>b</sup>	11.683 ± 2.085 <sup>a</sup>	<0.0001
C24-NH <sub>2</sub> GIPC	0.671 ± 0.231 <sup>b</sup>	nd	5.799 ± 1.609 <sup>a</sup>	0.481 ± 0.138 <sup>b</sup>	<0.0001
<b><i>Colon</i></b>					
C16-GluCer	nd	nd	nd	nd	-
C24-GluCer	0.151 ± 0.028 <sup>a</sup>	0.081 ± 0.044 <sup>a</sup>	0.125 ± 0.036 <sup>a</sup>	0.118 ± 0.069 <sup>a</sup>	0.0661
C16-NH <sub>2</sub> GIPC	nd	nd	nd	1.901 ± 0.625	<0.0001
C24-NH <sub>2</sub> GIPC	0.382 ± 0.214 <sup>a</sup>	nd	0.279 ± 0.072 <sup>a</sup>	0.123 ± 0.056 <sup>b</sup>	<0.0001

763

764 Values are means ± standard deviations for 6 and 9 mice in the NC and the three HC- groups,  
 765 respectively. Mean values within a row, not sharing a same superscript letter, were  
 766 significantly different at *P*<0.05; nd, not detected.


767 NC, normo-caloric; HC, hyper-caloric; Con, control; CamC24, camelina meal C24 (from the  
 768 commercial Céline cultivar rich in C24 fatty acids); CamC16, camelina meal C16 (from the  
 769 experimental LOH2 cultivar rich in C16 fatty acids).

770

771

772 **Figure 1. Body weight curve and body weight gain upon 5 week feeding with the**  
773 **experimental diets.**

	NC	HC-Con	HC-CamC24	HC-CamC16	P value
Weight gain (g)	3.47±1.06 <sup>b</sup>	8.78±2.98 <sup>a</sup>	5.21±1.24 <sup>b</sup>	5.08±1.07 <sup>b</sup>	<0.0001




774

775

776 Figure 2. Plasma kinetics of glucose and insulin during an OGTT after 3 weeks on the  
777 experimental diets.

778



779

780

781

782

783 **Legend to Figures.**

784

785 **Figure 1. Body weight curve.**

786 Body weight (g) was measured longitudinally in the fed state for 37d. At d0, after they were  
787 acclimated to local conditions for 1 week, mice that have been given progressively the HC-  
788 Con diet during this 1<sup>st</sup> week, were switched to the HC-Con, HC-CamC24 and HC-CamC16  
789 according to their experimental group.

790 Values are means  $\pm$  standard deviations for 6 and 9 mice in the NC and the three HC- groups,  
791 respectively.

792 NC, normo-caloric; HC, hyper-caloric; Con, control; CamC24, camelina meal C24 (from the  
793 commercial Céline cultivar rich in C24 fatty acids); CamC16, camelina meal C16 (from the  
794 experimental LOH2 cultivar rich in C16 fatty acids).

795

796

797 **Figure 2. Plasma kinetics of glucose and insulin during an OGTT after 3 weeks on the**  
798 **experimental diets.**

799 Glycemia (Panel A) and insulinemia (Panel B) have been measured for 120 min and their  
800 respective area under the curve (AUC) were calculated over the same period of time (Panels  
801 B and D). Values are means  $\pm$  standard deviations for 6 and 9 mice in the NC and the three  
802 HC- groups, respectively. Mean AUC values not sharing a same superscript letter, were  
803 significantly different at  $P < 0.05$ .



804 NC, normo-caloric; HC, hyper-caloric; Con, control; CamC24, camelina meal C24 (from the  
805 commercial Céline cultivar rich in C24 fatty acids); CamC16, camelina meal C16 (from the  
806 experimental LOH2 cultivar rich in C16 fatty acids).

807

808

809

810

811

812